Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

383.12USD
14 Dec 2017
Change (% chg)

$-3.55 (-0.92%)
Prev Close
$386.67
Open
$388.06
Day's High
$388.64
Day's Low
$380.89
Volume
152,521
Avg. Vol
285,876
52-wk High
$543.50
52-wk Low
$340.13

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $41,788.64
Shares Outstanding(Mil.): 107.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

France's Sanofi pins hopes on new drugs after setbacks

PARIS Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.

Dec 13 2017

UPDATE 4-France's Sanofi pins hopes on new drugs after setbacks

* CEO says company on track to sell European generics unit (Adds CEO comments, details, updates shares)

Dec 13 2017

BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous Squamous Cell Carcinoma

* REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

Dec 13 2017

BRIEF-Regeneron Announces FDA Acceptance Of SBLA Filing For 12-Week Dosing Of Eylea(Aflibercept) Injection For Patients With Wet AMD

* REGENERON ANNOUNCES FDA ACCEPTANCE OF SBLA FILING FOR 12-WEEK DOSING OF EYLEA® (AFLIBERCEPT) INJECTION FOR PATIENTS WITH WET AMD

Dec 11 2017

BRIEF-Regeneron And Decibel Therapeutics Announce Strategic Collaboration

* REGENERON AND DECIBEL THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP THERAPEUTICS FOR HEARING LOSS AND TINNITUS

Nov 29 2017

Regeneron drops eye-drug combination as Novartis chases Eylea

Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.

Nov 27 2017

Regeneron drops eye-drug combination as Novartis chases Eylea

Nov 27 Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.

Nov 27 2017

Swiss stocks - Factors to watch on Nov 13

ZURICH, Nov 13 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 9,159 points on Monday, according to premarket indications by bank Julius Baer .

Nov 13 2017

German stocks - Factors to watch on November 13

BERLIN/FRANKFURT, Nov 13 The following are some of the factors that may move German stocks on Monday:

Nov 13 2017

Novartis posts eye drug data amid play for Eylea's turf

ZURICH Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Nov 10 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.80 -0.05
Pfizer Inc. (PFE.N) $37.20 +0.74
Bayer AG (BAYGn.DE) €106.50 +1.40
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.55 -0.22
Merck & Co., Inc. (MRK.N) $56.24 +0.23
Amgen, Inc. (AMGN.OQ) $177.04 +2.12
Roche Holding Ltd. (ROG.S) CHF244.10 +2.40
Roche Holding Ltd. (RO.S) CHF243.40 +0.90
Eli Lilly and Co (LLY.N) $86.54 +0.04

Earnings vs. Estimates